Alphamab Oncology (HK:9966) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Alphamab Oncology has announced encouraging results from its phase I/II clinical trial, JSKN003-102, for treating advanced solid tumors, which were presented at the 2024 ASCO Annual Meeting. The study showed that JSKN003 was well-tolerated with a low occurrence of serious side effects and demonstrated a 51.1% objective response rate among heavily pretreated patients, including those with low HER2 expression and prior anti-HER2 treatments.
For further insights into HK:9966 stock, check out TipRanks’ Stock Analysis page.